Cis-platinum (CDDP) plus etoposide (VP-16-213) and treatment of disseminated neuroblastoma
Helson, L.
Anticancer Research 6(6): 1337-1340
1986
ISSN/ISBN: 0250-7005 PMID: 3813490 Document Number: 269906
Ten patients with neuroblastoma were treated with a standard pulsed administration schedule of cis-platinum and etoposide (VP16-213). Two patients are experiencing good partial responses lasting over 8 months. One other patient had a partial response. Toxicity was mild and limited to high frequency hearing loss, temporary increase in blood urea nitrogen, and myelosuppression. These data may be useful to compare with data from other more aggressive or different administration schedules of the drug combination.
Document emailed within 1 workday
Related Documents
Murakami, F.; Kiyozuka, Y.; Nishimura, H.; Imamura, K.; Yakushiji, M.; Noda, T.; Adachi, S.; Ito, K.; Tamori, N.; Shintani, M. 1993: Etoposide/cis-platinum (CDDP) combined chemotherapy for ovarian cancer: evaluation of optimum schedule for CDDP administration in chronic continuous exposure of ovarian cancer cells to low-dose etoposide in vitro Nihon Sanka Fujinka Gakkai Zasshi 45(2): 125-132Endo, K.; Akamatsu, K.; Matsumoto, T.; Morikawa, K.; Koizumi, M.; Mitsui, H.; Koizumi, K. 1992: Antitumor effects of three platinum complexes, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)-platinum (II) monohydrate (DWA2114R), cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) (CBDCA) and cis-diamminedichloroplatinum(II) (CDDP), in mice Anticancer Research 12(1): 49-58
Yuki, K.; Kodama, Y.; Emoto, K.; Yukawa, O.; Onda, J.; Uozumi, T. 1989: A case report of advanced malignant mixed germ cell tumor of parasellar origin indicating marked efficacy of a salvage combined chemotherapy of CDDP and etoposide and subsequent chemotherapy using oral etoposide Gan to Kagaku Ryoho. Cancer and ChemoTherapy 16(8 Pt 1): 2651-2654
Ohnuma, N.; Takahashi, H.; Maie, M.; Etoh, T.; Tanabe, M.; Kuriyama, Y. 1987: Effectiveness of cis-dichlorodiammine-platinum in the treatment of advanced neuroblastoma Gan to Kagaku Ryoho. Cancer and ChemoTherapy 14(10): 2876-2880
Bilgi, O.; Karagoz, B.; Alacacioglu, A.; Ozgun, A.; Tuncel, T.; Gokhan-Kandemir, E. 2010: Irinotecan and cisplatin vs. cyclophosphamide, doxorubicin, and vincristine as second-line treatment after platinum and etoposide in small-cell lung cancer Journal of BUON: Official Journal of the Balkan Union of Oncology 15(2): 395
Hayakawa, M.; Morise, K.; Oka, Y.; Saito, H. 1987: Combination chemotherapy of UFT, etoposide and CDDP in advanced gastric cancer Gan no Rinsho. Japan Journal of Cancer Clinics 33(7): 793-798
Sagawa, T.; Yamashita, K.; Kawamura, M.; Shimizu, T. 1986: The effect of cis-platinum (CDDP) on methotrexate-resistant choriocarcinoma cell line Nihon Sanka Fujinka Gakkai Zasshi 38(2): 203-209
Prajda, N.; Kralovánszky, J.; Gal, F.; Kiss, F.; Kerpel-Fronius, S. 1989: Evaluation of side effects of platinum complexes (CDDP, CBDCA, CHIP) on rat bone marrow In Vivo 3(4): 267-270
Kobayashi, M.; Ishikawa, Y.; Noda, M.; Hattori, T.; Okano, S.; Ito, T. 1986: Continuous intravenous infusion therapy of cis-diamminedichloroplatinum (CDDP) in children with neuroblastoma Gan to Kagaku Ryoho. Cancer and ChemoTherapy 13(11): 3283-3286
Kato, M.; Kinoshita, K.; Sawa, T.; Yoshimitsu, S.; Tomita, F.; Takano, Y.; Segawa, M.; Ohyama, S.; Yonemura, Y.; Miwa, K. 1990: Neoadjuvant chemotherapy of far advanced gastric cancer--effect of preoperative chemotherapy by PMUE (CDDP, MMC, UFT, etoposide Gan to Kagaku Ryoho. Cancer and ChemoTherapy 17(3 Part 1): 391-396
Wachters, F.M.; Van Der Graaf, W.T.A.; Groen, H.J.M. 2004: Cardiotoxicity in advanced non-small cell lung cancer patients treated with platinum and non-platinum based combinations as first-line treatment Anticancer Research 24(3b): 2079-2083
Kamani, N.; August, C.S.; Bunin, N.; Leahey, A.; Bayever, E.; Goldwein, J.; Zusman, J.; Evans, A.E.; Angio, G.D. 1996: A study of thiotepa, etoposide and fractionated total body irradiation as a preparative regimen prior to bone marrow transplantation for poor prognosis patients with neuroblastoma Bone Marrow Transplantation 17(6): 911-916
Hayes, F.A.; Green, A.A.; Mauer, A.M. 1977: Correlation of cell kinetic and clinical response to chemotherapy in disseminated neuroblastoma Cancer Research 37(10): 3766-3770
Gottstein, C.; Schön, G.; Tawadros, S.; Kube, D.; Wargalla-Plate, U.C.; Hansmann, M.L.; Wacker, H.H.; Berthold, F.; Diehl, V.; Engert, A. 1994: Antidisialoganglioside ricin A-chain immunotoxins show potent antitumor effects in vitro and in a disseminated human neuroblastoma severe combined immunodeficiency mouse model Cancer Research 54(23): 6186-6193
Hande, K.; Anthony, L.; Hamilton, R.; Bennett, R.; Sweetman, B.; Branch, R. 1988: Identification of etoposide glucuronide as a major metabolite of etoposide in the rat and rabbit Cancer Research 48(7): 1829-1834
Ota, K.; Oguma, T.; Shimamura, K. 1994: Pharmacokinetics of platinum in cancer patients following intravenous infusion of cis-diammine(glycolato)platinum, 254-S Anticancer Research 14(3b): 1383-1387
Winograd, B.; Vermorken, J.B.; ten Bokkel Huinink, W.W.; Simonetti, G.; Gall, H.E.; Knobf, M.K.; van der Vijgh, W.J.; McVie, J.G.; Pinedo, H.M. 1986: Phase i study of ethylenediamine platinum(II) malonate (NSC 146 068), a second generation platinum analogue Cancer Research 46(4 Part 2): 2148-2151
Saegusa, Y.; Eriguchi, M.; Kidani, Y.; Matsuzawa, A.; Takeda, Y. 2001: Antitumor effects of a new lipophilic platinum compound, trans-bis(n-valerato)(1R,2R-cyclohexanediamine)(oxalato)platinum(IV), in mice Anticancer Research 21(1a): 245-252
Linasmita, V.; Wilailak, S.; Srisupundit, S.; Tangtrakul, S.; Bullangpoti, S.; Israngura, N. 1998: Epithelial ovarian cancer treated by platinum or platinum analogue with cyclophosphamide: experience in Ramathibodi Hospital Journal of the Medical Association of Thailand 81(1): 10-16
Hagiwara, A.; Takahashi, T.; Sawai, K.; Seiki, K.; Ito, M.; Okano, S.; Sakakura, C.; Shobayashi, S.; Muranishi, S.; Tomoda, H. 1992: Enhanced therapeutic efficacy of intralymph-nodal etoposide on distal lymph node metastases using a new dosage format--activated carbon particles adsorbing etoposide Anti-Cancer Drug Design 7(2): 163-168